Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $11.52, for a total value of $1,152,000.00. Following the completion of the sale, the chief executive officer directly owned 1,462,223 shares in the company, valued at $16,844,808.96. This trade represents a 6.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Friday, June 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.45, for a total value of $1,145,000.00.
• On Tuesday, June 3rd, Eric Venker sold 566,278 shares of Roivant Sciences stock. The shares were sold at an average price of $11.22, for a total transaction of $6,353,639.16.
• On Monday, June 2nd, Eric Venker sold 433,722 shares of Roivant Sciences stock. The stock was sold at an average price of $11.07, for a total value of $4,801,302.54.
• On Tuesday, May 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.95, for a total transaction of $1,095,000.00.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV traded up $0.17 during mid-day trading on Friday, reaching $11.55. The company's stock had a trading volume of 4,358,236 shares, compared to its average volume of 6,275,449. The stock has a 50-day moving average of $11.22 and a two-hundred day moving average of $10.84. The stock has a market capitalization of $7.85 billion, a P/E ratio of -46.20 and a beta of 1.15. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The firm had revenue of $7.57 million during the quarter, compared to analysts' expectations of $62.17 million. Roivant Sciences had a negative net margin of 225.71% and a negative return on equity of 14.76%. During the same period last year, the company earned ($0.23) EPS. Analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

Several large investors have recently added to or reduced their stakes in the business. Norges Bank acquired a new stake in Roivant Sciences in the fourth quarter valued at $52,443,000. Nuveen LLC purchased a new stake in Roivant Sciences during the first quarter worth approximately $31,988,000. Invesco Ltd. lifted its stake in Roivant Sciences by 49.7% during the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock worth $112,563,000 after purchasing an additional 3,159,603 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock valued at $521,553,000 after purchasing an additional 2,404,232 shares in the last quarter. Finally, TOMS Capital Investment Management LP increased its stake in Roivant Sciences by 46.6% in the fourth quarter. TOMS Capital Investment Management LP now owns 5,885,000 shares of the company's stock valued at $69,620,000 after purchasing an additional 1,870,000 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. The Goldman Sachs Group raised shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 target price for the company in a report on Thursday, July 10th. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, June 18th.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.